Insiders who reported open-market trades in the last 12 months at the companies Katherine Stueland files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Keith A. Meister - $74.03M in WGS purchases and sales in the last 12 months
Casdin Capital, LLC - $32.57M in WGS purchases and sales in the last 12 months
Joshua Ruch - $6.09M in WGS purchases and sales in the last 12 months
Kevin Feeley - $2.60M in WGS purchases and sales in the last 12 months
Bryan Dechairo - $851K in WGS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Katherine Stueland is a corporate insider, tracked as CHIEF EXECUTIVE OFFICER, Director of GeneDx Holdings Corp. (WGS). InsiderAlpha holds 22 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Katherine Stueland submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Katherine Stueland been buying or selling stock?
Recorded transactions: 0 open-market purchases and 59 open-market sales ($18.33M) across all tracked filings.
Katherine Stueland is CHIEF EXECUTIVE OFFICER, Director of GeneDx Holdings Corp. (WGS). 22 SEC Form 4 filings on record going back to 2024, most recently on 18 September 2026. Most recent open-market trade: sold $301K of WGS on 18 September 2026. Lifetime open-market sales: $18.33M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Katherine Stueland.
InsiderAlpha's records for Katherine Stueland go back to 2024: 22 primary Form 4 filings, an average of 7.3 per year. 13 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
